What is IRD (IRD) stock price today?

IRD (IRD) is currently trading at $4.45, up 16.19% today.

What is IRD P/E ratio?

IRD's P/E ratio is -2.99. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is IRD return on equity (ROE)?

IRD's return on equity (ROE) is -333.33%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is IRD's market cap?

IRD has a market capitalization of $367.42M.

NASDAQ · Biotechnology

IRD (IRD) Stock

$4.45 +16.19% NASDAQ: IRD Healthcare

Valuation

Metric	Value
Price	$4.45
Market Cap	$367.42M
P/E Ratio	-2.99
P/B Ratio	-27.94
P/S Ratio	31.83
EPS (TTM)	$-0.80
52-Week High	$5.81
52-Week Low	$1.17
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-333.33%
ROA	-115.75%
ROCE	-59.29%
Gross Margin	-278.57%
Operating Margin	-278.57%
Net Margin	-892.36%
Debt/Equity	-2.69
Current Ratio	6.25

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$1.0M	$40.0M	$19.0M	$11.0M	$14.0M
Operating Profit	$-23.0M	$18.0M	$-11.0M	$-62.0M	$-39.0M
Net Profit	$-57.0M	$18.0M	$-10.0M	$-58.0M	$-50.0M
EPS	$-3.82	$0.87	$-0.46	$-2.15	$-0.80
Op Margin	-3854.8%	45.7%	-55.5%	-564.7%	-271.9%

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$26.0M	$49.0M	$54.0M	$37.0M	$50.0M
Total Liabilities	$4.0M	$3.0M	$4.0M	$30.0M	$35.0M
Cash	$25.0M	$43.0M	$51.0M	$30.0M	$45.0M
Borrowings	$1.0M	$0	$0	$0	$0

Latest News

Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results GlobeNewswire · Jul 9, 2026 Opus Genetics Unlocks Key Milestone With US FDA Alignment on OPGx-LCA5 Phase 3, Wedbush Says MT Newswires · Jul 6, 2026 Sector Update: Healthcare Stocks Mixed Premarket Monday MT Newswires · Jul 6, 2026 Opus Genetics Announces FDA Alignment on Phase 3 Registrational Trial Design for OPGx-LCA5 in LCA5-Associated Inherited Retinal Disease GlobeNewswire · Jul 6, 2026 RBC Capital Bullish On Opus Genetics (IRD) Amid Limited Competition And De-Risked Setup Insider Monkey · Jul 5, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-19.0M	$14.0M	$-1.0M	$-26.0M	$-35.0M
Investing Cash Flow	$0	$0	$0	$1.0M	$0
Financing Cash Flow	$-1.0M	$0	$0	$0	$0
Net Cash Flow	$8.0M	$18.0M	$8.0M	$-20.0M	$15.0M
Free Cash Flow	$-19.0M	$14.0M	$-1.0M	$-26.0M	$-35.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.07
EV / EBITDA	-2.48
FCF Yield	-12.96%
Quick Ratio	12.19
Interest Coverage	-19.11
Return 1Y	143.33%
Return 3Y	-25.70%
Return 5Y	-10.33%

Ownership

Insiders Held11.06%

Institutions Held55.14%

Institutions Float Held62.00%

Institutional Holder	Shares	Report Date
Caligan Partners, LP	6,075,028	2026-03-31
Adage Capital Partners GP L.L.C.	6,029,775	2026-03-31
Bios Capital Management, LP	3,683,429	2026-03-31
Balyasny Asset Management LP	2,718,029	2026-03-31
Millennium Management Llc	2,630,432	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ABOS	$3.10	+6.16%	-1.17	$223.91M	0.00%
AGEN	$8.09	+1.25%	3.04	$336.89M	0.00%
ALEC	$2.72	+13.33%	-1.58	$301.99M	0.00%
CGTX	$1.05	+3.96%	-3.94	$93.97M	0.00%
HURA	$2.09	+2.96%	-3.75	$133.10M	0.00%

About IRD

IRD is led by CEO George Magrath, employs 18 people, headquartered in US, publicly traded since 2015.

IRD stock trades at $4.45 with a market capitalization of $367.42M. The stock is valued at a price-to-earnings (P/E) ratio of -2.99, price-to-book of -27.94, price-to-sales of 31.83. Over the past 52 weeks the stock has ranged between $1.17 and $5.81, and currently trades 23.4% below its 52-week high.

On profitability, IRD generates a return on equity (ROE) of -333.33%, return on capital employed of -59.29%, an operating margin of -278.57%, a net profit margin of -892.36%.

Related Healthcare Stocks

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides